Socié G, Piprot-Chauffat C, Schlienger M, Legars D, Thurel C, Mikol J, Ifran N, Brière J, Pene F, Gindrey-Vie B
Centre des Tumeurs, Hôpital Tenon, Paris, France.
Cancer. 1990 Jan 15;65(2):322-6. doi: 10.1002/1097-0142(19900115)65:2<322::aid-cncr2820650223>3.0.co;2-d.
From January 1979 to December 1987, 35 cases of primary central nervous system lymphoma (CNS-L) were treated. We recently reviewed these cases focusing on treatment results, treatment modalities, and radiotherapy (RT) or chemotherapy-radiotherapy (CT-RT). Variables such as age, risk factors, presenting symptoms, and histologic condition (all were high-grade or intermediate-grade non-Hodgkin's lymphomas [NHL]) and radiologic data were similar to those of series reported previously. The median survival time was 36 months (+/- 0.2 months) and the disease-free survival (DFS) time was 16 months (+/- 0.12 months). Twelve of 32 patients evaluable for treatment results experienced a recurrence (all but one occurred in the CNS). The DFS rate was 70% for the CT-RT group and 50% for the RT group (median follow-up time, 24 months). Therapeutic results in CNS-L are discussed with special emphasis on a putative role of CT in the management of this rare type of tumor.
1979年1月至1987年12月，共治疗了35例原发性中枢神经系统淋巴瘤（CNS-L）。我们最近回顾了这些病例，重点关注治疗结果、治疗方式以及放疗（RT）或化疗联合放疗（CT-RT）。年龄、危险因素、首发症状、组织学状况（均为高级别或中级别非霍奇金淋巴瘤[NHL]）以及放射学数据等变量与先前报道的系列病例相似。中位生存时间为36个月（±0.2个月），无病生存（DFS）时间为16个月（±0.12个月）。在可评估治疗结果的32例患者中，有12例出现复发（除1例外均发生在中枢神经系统）。CT-RT组的DFS率为70%，RT组为50%（中位随访时间为24个月）。本文讨论了CNS-L的治疗结果，特别强调了CT在这种罕见肿瘤治疗中的假定作用。
